• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

磷脂链长度、浓度、电荷及囊泡大小对肺部胰岛素吸收的影响。

Effects of phospholipid chain length, concentration, charge, and vesicle size on pulmonary insulin absorption.

作者信息

Li Y, Mitra A K

机构信息

Central Pharmaceuticals, Inc., Seymour, Indiana 47274, USA.

出版信息

Pharm Res. 1996 Jan;13(1):76-9. doi: 10.1023/a:1016029317299.

DOI:10.1023/a:1016029317299
PMID:8668683
Abstract

PURPOSE

Non drug loaded lipid vesicles have been investigated as promoters of pulmonary insulin absorption.

METHODS

Physical mixtures of liposomes with insulin were delivered intratracheally to rats by direct instillation method at an insulin dose level of 1 U/kg.

RESULTS

The overall hypoglycemic response, represented by area above the curve (AAC), correlated linearly with the lipid concentration for both the neutral and charged liposome-insulin preparations. The strongest response was observed with the positively charged liposomes followed by negatively charged and neutral liposome-insulin mixtures. Further toxicological studies indicated that charge-inducing agents, i.e., stearylamine and dicetylphosphate, can cause apparent disruption of pulmonary epithelial cells. From the difference of overall hypoglycemic response (AAC) among various formulations, it appears that the stronger hypoglycemic effect following positively charged liposome-insulin mixture is due to the membrane destabilizing effect on stearylamine. Optimum hypoglycemic effect was observed with a medium acyl-chain lipid (C10). The cumulative hypoglycemic response appeared to correlate inversely with the acyl carbon number of the phospholipid component from C10 to C18. The overall hypoglycemic effect does not appear to change within the liposomal size range of 0.1 micron - 1.98 microns, indicating that insulin absorption following intratracheal instillation is independent of the vesicle size within the range studied.

CONCLUSIONS

Phospholipid promoted insulin pulmonary absorption is significantly dependent on the concentration, charge and acyl chain length of the phospholipids.

摘要

目的

已对未载药脂质囊泡作为肺部胰岛素吸收促进剂进行了研究。

方法

通过直接滴注法将脂质体与胰岛素的物理混合物经气管内给予大鼠,胰岛素剂量水平为1 U/kg。

结果

以曲线下面积(AAC)表示的总体降糖反应,对于中性和带电荷的脂质体 - 胰岛素制剂,均与脂质浓度呈线性相关。观察到带正电荷的脂质体产生的反应最强,其次是带负电荷的和中性的脂质体 - 胰岛素混合物。进一步的毒理学研究表明,电荷诱导剂,即硬脂胺和十六烷基磷酸酯,可导致肺上皮细胞明显破坏。从各种制剂之间总体降糖反应(AAC)的差异来看,带正电荷的脂质体 - 胰岛素混合物之后更强的降糖作用似乎是由于硬脂胺对膜的去稳定作用。使用中等酰基链脂质(C10)观察到最佳降糖效果。累积降糖反应似乎与磷脂成分从C10到C18的酰基碳原子数呈负相关。在所研究的脂质体大小范围0.1微米 - 1.98微米内,总体降糖效果似乎没有变化,这表明经气管内滴注后胰岛素的吸收在所研究的范围内与囊泡大小无关。

结论

磷脂促进胰岛素肺部吸收显著依赖于磷脂的浓度、电荷和酰基链长度。

相似文献

1
Effects of phospholipid chain length, concentration, charge, and vesicle size on pulmonary insulin absorption.磷脂链长度、浓度、电荷及囊泡大小对肺部胰岛素吸收的影响。
Pharm Res. 1996 Jan;13(1):76-9. doi: 10.1023/a:1016029317299.
2
Enhanced pulmonary delivery of insulin by lung lavage fluid and phospholipids.通过肺灌洗液和磷脂增强胰岛素的肺部递送。
Int J Pharm. 2001 Apr 17;217(1-2):25-31. doi: 10.1016/s0378-5173(01)00588-9.
3
Comparing the enhancement efficiency between liposomes and microbubbles for insulin pulmonary absorption.比较脂质体和微泡在胰岛素肺吸收中的增强效率。
Diabetes Technol Ther. 2011 Jul;13(7):759-65. doi: 10.1089/dia.2010.0231. Epub 2011 Apr 21.
4
Effect of pulmonary surfactant and phospholipid hexadecanol tyloxapol on recombinant human-insulin absorption from intratracheally administered dry powders in diabetic rats.肺表面活性物质和磷脂十六醇聚氧乙烯醚对糖尿病大鼠气管内给药干粉中重组人胰岛素吸收的影响。
Chem Pharm Bull (Tokyo). 2010 Dec;58(12):1612-6. doi: 10.1248/cpb.58.1612.
5
Pulmonary delivery of free and liposomal insulin.游离胰岛素和脂质体胰岛素的肺部给药
Pharm Res. 1993 Feb;10(2):228-32. doi: 10.1023/a:1018934810512.
6
Facilitation of pulmonary insulin absorption by H-MAP: pharmacokinetics and pharmacodynamics in rats.H-MAP促进肺部胰岛素吸收:大鼠体内的药代动力学和药效学
Pharm Res. 2001 Dec;18(12):1677-84. doi: 10.1023/a:1013362227548.
7
Pulmonary delivery of insulin by liposomal carriers.脂质体载体介导的胰岛素肺部给药
J Control Release. 2006 Jun 12;113(1):9-14. doi: 10.1016/j.jconrel.2006.03.014. Epub 2006 Mar 28.
8
Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose.载胰岛素脂质体在大鼠中的降血糖活性和口服生物利用度:胆酸盐类型、粒径和给药剂量的影响。
Eur J Pharm Biopharm. 2012 Jun;81(2):265-72. doi: 10.1016/j.ejpb.2012.02.009. Epub 2012 Feb 18.
9
[Pulmonary delivery of insulin lipid suspension].胰岛素脂质混悬液的肺部给药
Yao Xue Xue Bao. 2002 May;37(5):378-82.
10
[Studies on the insulin-liposomes double-coated by chitosan and chitosan-EDTA conjugates].壳聚糖与壳聚糖-乙二胺四乙酸共轭物双包被胰岛素脂质体的研究
Yao Xue Xue Bao. 2004 Nov;39(11):933-8.

引用本文的文献

1
Treatment of lean and diet-induced obesity (DIO) mice with a novel stable obestatin analogue alters plasma metabolite levels as detected by untargeted LC-MS metabolomics.用一种新型稳定的肥胖抑制素类似物治疗瘦型和饮食诱导肥胖(DIO)小鼠,通过非靶向液相色谱-质谱代谢组学检测发现可改变血浆代谢物水平。
Metabolomics. 2016;12:124. doi: 10.1007/s11306-016-1063-0. Epub 2016 Jul 5.
2
Lipidomic Profiling of Liver Tissue from Obesity-Prone and Obesity-Resistant Mice Fed a High Fat Diet.喂食高脂饮食的肥胖倾向型和肥胖抵抗型小鼠肝脏组织的脂质组学分析
Sci Rep. 2015 Nov 23;5:16984. doi: 10.1038/srep16984.
3
Improvement of dissolution and hypoglycemic efficacy of glimepiride by different carriers.

本文引用的文献

1
Pulmonary delivery of free and liposomal insulin.游离胰岛素和脂质体胰岛素的肺部给药
Pharm Res. 1993 Feb;10(2):228-32. doi: 10.1023/a:1018934810512.
2
Binding of insulin to the external surface of liposomes. Effect of surface curvature, temperature, and lipid composition.
Biochim Biophys Acta. 1982 Aug 12;689(3):490-8. doi: 10.1016/0005-2736(82)90307-8.
3
Diffusion of univalent ions across the lamellae of swollen phospholipids.单价离子在肿胀磷脂片层间的扩散。
J Mol Biol. 1965 Aug;13(1):238-52. doi: 10.1016/s0022-2836(65)80093-6.
采用不同载体改善格列美脲的溶出度和降血糖效果。
AAPS PharmSciTech. 2012 Sep;13(3):1013-23. doi: 10.1208/s12249-012-9812-5. Epub 2012 Jul 28.
4
Nanotechnology: intelligent design to treat complex disease.纳米技术:治疗复杂疾病的智能设计
Pharm Res. 2006 Jul;23(7):1417-50. doi: 10.1007/s11095-006-0284-8. Epub 2006 Jun 21.
5
Carrier-based strategies for targeting protein and peptide drugs to the lungs.将蛋白质和肽类药物靶向输送至肺部的基于载体的策略。
AAPS J. 2005 Mar 24;7(1):E20-41. doi: 10.1208/aapsj070104.
6
The lung as a route for systemic delivery of therapeutic proteins and peptides.肺作为治疗性蛋白质和肽全身递送的途径。
Respir Res. 2001;2(4):198-209. doi: 10.1186/rr58. Epub 2001 Apr 12.
4
Lymphatic transport of liposome-encapsulated agents: effects of liposome size following intraperitoneal administration.脂质体包裹药物的淋巴转运:腹腔注射后脂质体大小的影响
J Pharm Sci. 1985 Sep;74(9):915-21. doi: 10.1002/jps.2600740902.
5
Peptides are better absorbed from the lung than the gut in the rat.在大鼠体内,肽从肺部的吸收比从肠道更好。
Pharm Res. 1992 Aug;9(8):1103-6. doi: 10.1023/a:1015879116950.
6
Liposome toxicity in the mouse central nervous system.
J Neurol Sci. 1977 Mar;31(2):173-9. doi: 10.1016/0022-510x(77)90104-6.
7
Structural basis for some permeability properties of the air--blood barrier.
Fed Proc. 1978 Sep;37(11):2471-8.